Abstract
BackgroundIrisin is an adipomyokine with a promising potential for the treatment of metabolic disturbances and endothelial dysfunction. This study aimed to explore the effect of irisin on metabolic and platelet functions, and to explore the possible involvement of soluble receptor of advanced glycation end product (sRAGE) in the type 2 diabetes mellitus (T2DM) rat model. Thirty-three adult male albino rats were divided into three groups: normal control, vehicle-treated T2DM group, and irisin-treated T2DM. At the end of the study period, metabolic parameters, platelet count, mean platelet volume, platelet distribution width, plateletcrit, and serum sRAGE were determined.ResultsIrisin significantly improved platelet function and metabolic derangements induced by T2DM and significantly increased sRAGE. sRAGE was significantly negatively associated with platelet function parameters and some glucometabolic parameters. Additionally, mean platelet volume showed a significant predictive value for the change in serum sRAGE.ConclusionsIrisin could have a protective role against diabetes-induced platelet dysfunction by increasing sRAGE levels, indicating the potential beneficial effects of sRAGE in the type 2 diabetic rat model.
Highlights
Irisin is an adipomyokine with a promising potential for the treatment of metabolic disturbances and endothelial dysfunction
3.1 Effect of irisin treatment on metabolic parameters There was a significant increase in the final body weights (BW) of both diabetic groups (IIa and IIb) compared to Initial BW (g) Final BW (g) fasting blood glucose (FBG) Insulin HOMA-insulin resistance (IR) Total cholesterol (TC) TG high-density lipoprotein (HDL) Low-density lipoprotein (LDL) Very low-density lipoproteins (VLDL) sRAGES
Our results showed that irisin administration caused a significant reduction in serum glucose and insulin levels in STZ diabetic rats, which agrees with Liu et al [24], who explained that by the promotion of β cell proliferation
Summary
Irisin is an adipomyokine with a promising potential for the treatment of metabolic disturbances and endothelial dysfunction. This study aimed to explore the effect of irisin on metabolic and platelet functions, and to explore the possible involvement of soluble receptor of advanced glycation end product (sRAGE) in the type 2 dia‐ betes mellitus (T2DM) rat model. Type 2 diabetes mellitus (T2DM) is a serious, global metabolic health problem with a high prevalence and morbidity that is complicated by atherosclerosis and circulatory dysfunction [1]. Recent studies have shown that irisin is secreted from white adipose tissue and may regulate several physiological and metabolic pathways that protect against obesity and complications from insulin resistance (IR) [4, 5]. It has been reported that irisin has anti-inflammatory, anti-oxidative, and anti-apoptotic properties, which play a significant role in the protection from many diseases, such as atherosclerosis and myocardial infarctions [5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Beni-Suef University Journal of Basic and Applied Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
